Traitement pharmacologique : enfin une solution adapté - FF3S

PRILIGY Etudes de Phase III :EP primaire et acquise efficacité comparablen = 957 n = 986 n = 955 n = 509 n = 511 n = 492 n = 957 n = 986 n = 955 n = 509 n = 511 n = 492InclusionFin d’étudeSD, standard deviation; IELT, intravaginal ejaculatory latency time; PE, premature ejaculation.aBased on pooled data from the 2 US studies, the international study, and the Asia-Pacific study.